The idea that a simple walk across a room could reveal the state of aging brain tissue may seem improbable — yet that is precisely what a large community-based study now suggests. For the roughly 16 million Americans currently living with measurable cognitive decline, tools that can flag neurodegeneration early, cheaply, and at scale have enormous clinical value. This work advances the case that physical performance tests belong in that toolkit.
Using data from the Healthy Aging Brain Study-Health Disparities cohort, researchers assessed 2,165 cognitively normal older adults — non-Hispanic Black, non-Hispanic white, and Hispanic participants with a mean age of roughly 65 — using two well-validated physical tests: the Timed Up and Go (TUG) and the Short Physical Performance Battery (SPPB). MRI-derived brain metrics — white matter hyperintensity volume (WMH), total brain volume (TBV), and hippocampal volume (HV) — were the primary outcomes. After Bonferroni correction, slower TUG times corresponded to greater WMH burden (β = 0.28), reduced TBV (β = −0.50), and reduced HV (β = −0.28). Better SPPB scores associated with larger TBV and lower WMH. Critically, these associations held with broadly similar magnitude across all three racial and ethnic groups examined.
The consistency across demographic groups is arguably the study's most consequential feature. Physical function tests are already known to vary by race and ethnicity — shaped by upstream social determinants like cumulative stress exposure and healthcare access — yet those disparities in test scores did not translate into inconsistent brain-body associations. This suggests TUG and SPPB capture a biologically shared pathway, plausibly through cerebrovascular health and gait-related neuromotor circuitry, rather than culturally specific artifacts. That said, the cross-sectional design precludes causal inference: brain volume loss could precede gait slowing, rather than the reverse. The cohort is also relatively young at 65, and effect sizes, while statistically significant, are modest, leaving open questions about clinical thresholds. Still, for a demographically diverse, community-based screening context, this is a confirmatory and practically meaningful finding — not paradigm-shifting, but a meaningful step toward equitable, scalable dementia risk stratification.
